ArticleMethods (San Diego, Calif.)2012
Sensitive PCR-based quantitation of cell-free circulating microRNAs.
Article in Methods (San Diego, Calif.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Exploring the Feasibility of Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Osteoarthritis: Challenges and Opportunities.International journal of molecular sciences · 2023Review
- Circulating microRNA as potential diagnostic and prognostic biomarkers of well-differentiated thyroid cancer: A review article.Cancer biomarkers : section A of Disease markers · 2023Review
- Circulating miR-146a expression as a non-invasive predictive biomarker for acute lymphoblastic leukemia.Scientific reports · 2021Article
- The Role of microRNA in Pancreatic Cancer.Biomedicines · 2021Review
- Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas.Diagnostics (Basel, Switzerland) · 2021Article
- Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples.PloS one · 2020Article
- Dose-response analysis of epigenetic, metabolic, and apical endpoints after short-term exposure to experimental hepatotoxicants.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2017Article
- Aberration of miRNAs Expression in Leukocytes from Sporadic Amyotrophic Lateral Sclerosis.Frontiers in molecular neuroscience · 2016Article
- Folate status, folate-related genes and serum miR-21 expression: Implications for miR-21 as a biomarker.BBA clinical · 2015Article
- Serum microRNAs as Potential Biomarkers of Juvenile Idiopathic Arthritis.Clinical rheumatology · 2015Article
- Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer.Pancreatic disorders & therapy · 2015Article
- Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.The Journal of molecular diagnostics : JMD · 2015Review
- Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer.Oncology letters · 2015Article
- An Improved Breast Epithelial Sampling Method for Molecular Profiling and Biomarker Analysis in Women at Risk for Breast Cancer.Breast cancer : basic and clinical research · 2015Article
- Issues and prospects of microRNA-based biomarkers in blood and other body fluids.Molecules (Basel, Switzerland) · 2014Review
- Standardizing analysis of circulating microRNA: clinical and biological relevance.Journal of cellular biochemistry · 2014Article
- Circulating nucleic acids as biomarkers of prostate cancer.Biomarkers in medicine · 2013Review
- Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223.Drug metabolism and disposition: the biological fate of chemicals · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cell-free microRNAs (miRNAs) that circulate in the blood are promising surrogate biomarkers of disease and physiological processes. The ease of quantifying specific miRNA species using made-to-order approaches based on Taq-polymerase has led to numerous studies that have identified changes in the abundance of circulating cell-free miRNA species that correlate with pathology or other events. The growing interest in developing miRNAs as blood biomarkers necessitates the careful consideration of the unique properties of such body fluids that can make the reproducible and quantitative assessment of RNA abundance challenging. For example, enzymes involved in the amplification and analysis of RNA can be affected by blood components that copurify with miRNA. Thus, if miRNAs are to be effectively utilized as biomarkers, it is important to establish standardized protocols for blood collection and miRNA analysis to ensure accurate quantitation. Here we outline several considerations, including the type of collection tube used in sampling, the influence of added anticoagulants and stabilizers, sample processing, enrichment of vesicular and other miRNA species, RNA extraction approaches and enzyme selection, that affect quantitation of miRNA isolated from plasma and should be considered in order to achieve reproducible, sensitive and accurate quantitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.